← Oncology Approval Tracker

FDA DECISION ·

Jaypirca

pirtobrutinib · Eli Lilly

Accelerated approvalNew therapyMantle cell lymphoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

For adults with relapsed or refractory mantle cell lymphoma after at least two systemic treatment lines, including a BTK inhibitor.

LAMPGEN ANALYSIS

Why it matters

The approval introduced a noncovalent BTK inhibitor after prior BTK-directed treatment.

What research teams should watch

Verify previous BTK inhibitor exposure and track the FDA status of this accelerated indication separately from CLL.

PRIMARY RECORDS

Sources